Deals Of The Week: Forma/Boehringer Ingelheim, Biogen/Isis, Alnylam/Arrowhead
Industry business-development executives rang in the New Year with a half-dozen deals, including Forma’s second big partnership in six months and a joint licensing agreement between Alnylam and Arrowhead.
You may also be interested in...
Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.